Filip Lim

List of Publications by Year
in descending order

76 papers	3,316 citations	147726 31 h-index	149623 56 g-index
76 all docs	76 docs citations	76 times ranked	3360 citing authors

#	Article	IF	Citations
1	Regulated Release and Polarized Localization of Brain-Derived Neurotrophic Factor in Hippocampal Neurons. Molecular and Cellular Neurosciences, 1996, 7, 222-238.	1.0	319
2	Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. Journal of Virology, 1996, 70, 7190-7197.	1.5	259
3	FTDP-17 Mutations in tau Transgenic Mice Provoke Lysosomal Abnormalities and Tau Filaments in Forebrain. Molecular and Cellular Neurosciences, 2001, 18, 702-714.	1.0	207
4	Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. Journal of Alzheimer's Disease, 2003, 5, 301-308.	1.2	172
5	Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiology of Disease, 2005, 20, 814-822.	2.1	163
6	Generation of High-Titer Defective HSV-1 Vectors Using an IE 2 Deletion Mutant and Quantitative Study of Expression in Cultured Cortical Cells. BioTechniques, 1996, 20, 460-469.	0.8	136
7	DNA binding by c-Ets-1, but not v-Ets, is repressed by an intramolecular mechanism.. EMBO Journal, 1992, 11, 643-652.	3.5	132
8	Rab17 Regulates Membrane Trafficking through Apical Recycling Endosomes in Polarized Epithelial Cells. Journal of Cell Biology, 1998, 140, 1039-1053.	2.3	132
9	Generation of three-dimensional multiple spheroid model of olfactory ensheathing cells using floating liquid marbles. Scientific Reports, 2015, 5, 15083.	1.6	113
10	Sequence and domain structure of yeast pyruvate carboxylase.. Journal of Biological Chemistry, 1988, 263, 11493-11497.	1.6	91
11	Characterization of a double (amyloid precursor protein-tau) transgenic: Tau phosphorylation and aggregation. Neuroscience, 2005, 130, 339-347.	1.1	78
12	Sequence and domain structure of yeast pyruvate carboxylase. Journal of Biological Chemistry, 1988, 263, 11493-7.	1.6	73
13	The inhibition of phosphatidylinositol-3-kinase induces neurite retraction and activates GSK3. Journal of Neurochemistry, 2001, 78, 468-481.	2.1	68
14	Mitochondrial Hexokinase II Promotes Neuronal Survival and Acts Downstream of Glycogen Synthase Kinase-3. Journal of Biological Chemistry, 2009, 284, 3001-3011.	1.6	64
15	Infectious Delivery and Expression of a 135â€‰kb Human FRDA Genomic DNA Locus Complements Friedreich's Ataxia Deficiency in Human Cells. Molecular Therapy, 2007, 15, 248-254.	3.7	58
16	Binding of Hsp90 to Tau Promotes a Conformational Change and Aggregation of Tau Protein. Journal of Alzheimer's Disease, 2009, 17, 319-325.	1.2	57
17	General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination. Current Gene Therapy, 2014, 13, 385-394.	0.9	57
18	Low-Dose Curcumin Stimulates Proliferation, Migration and Phagocytic Activity of Olfactory Ensheathing Cells. PLoS ONE, 2014, 9, e111787.	1.1	56

#	Article	IF	Citations
19	Myb protein binds to multiple sites in the human T cell lymphotropic virus type 1 long terminal repeat and transactivates LTR-mediated expression. Virology, 1992, 186, 764-769.	1.1	55
20	Tau Function and Dysfunction in Neurons. Molecular Neurobiology, 2002, 25, 213-232.	1.9	54
21	Glycogen Synthase Kinase-3 Modulates Neurite Outgrowth in Cultured Neurons: Possible Implications for Neurite Pathology in Alzheimer's Disease. Journal of Alzheimer's Disease, 1999, 1, 361-378.	1.2	53
22	The FTDP-17-Linked Mutation R406W Abolishes the Interaction of Phosphorylated Tau with Microtubules. Journal of Neurochemistry, 2002, 74, 2583-2589.	2.1	53
23	Functional Recovery in a Friedreich's Ataxia Mouse Model by Frataxin Gene Transfer Using an HSV-1 Amplicon Vector. Molecular Therapy, 2007, 15, 1072-1078.	3.7	52
24	A clonal cell line from immortalized olfactory ensheathing glia promotes functional recovery in the injured spinal cord. Molecular Therapy, 2006, 13, 598-608.	3.7	49
25	Tau in neurodegenerative diseases: Tau phosphorylation and assembly. Neurotoxicity Research, 2004, 6, 477-482.	1.3	47
26	Differentiation of a human neuroblastoma into neuron-like cells increases their susceptibility to transduction by herpesviral vectors. Journal of Neuroscience Research, 2006, 84, 755-767.	1.3	45
27	Foot-and-Mouth Disease Virus Lacking the VP1 G-H Loop: The Mutant Spectrum Uncovers Interactions among Antigenic Sites for Fitness Gain. Virology, 2001, 288, 192-202.	1.1	44
28	Immortalized olfactory ensheathing glia promote axonal regeneration of rat retinal ganglion neurons. Journal of Neurochemistry, 2003, 85, 861-871.	2.1	40
29	Electron microscopic localization of pyruvate carboxylase in rat liver and Saccharomyces cerevisiae by immunogold procedures. Archives of Biochemistry and Biophysics, 1991, 290, 197-201.	1.4	39
30	Pyruvate carboxylase in the yeast pyc mutant. Archives of Biochemistry and Biophysics, 1987, 258, 259-264.	1.4	36
31	Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease. Journal of Neuroscience Research, 2010, 88, 1943-1950.	1.3	33
32	Highly Efficient and Specific Gene Transfer to Purkinje CellsIn VivoUsing a Herpes Simplex Virus I Amplicon. Human Gene Therapy, 2002, 13, 665-674.	1.4	30
33	Reversibly immortalized human olfactory ensheathing glia from an elderly donor maintain neuroregenerative capacity. Glia, 2010, 58, 546-558.	2.5	29
34	Pyruvate carboxylase from Saccharomyces cerevisiae. Quaternary structure, effects of allosteric ligands and binding of avidin. FEBS Journal, 1986, 156, 15-22.	0.2	28
35	Prevention of Senescence Progression in Reversibly Immortalized Human Ensheathing Glia Permits Their Survival After Deimmortalization. Molecular Therapy, 2010, 18, 394-403.	3.7	27
36	Infectious delivery and long-term persistence of transgene expression in the brain by a 135-kb iBAC-FXN genomic DNA expression vector. Gene Therapy, 2011, 18, 1015-1019.	2.3	24

#	Article	IF	Citations
37	High level of amyloid precursor protein expression in neurite-promoting olfactory ensheathing glia (OEG) and OEG-derived cell lines. Journal of Neuroscience Research, 2003, 71, 871-881.	1.3	21
38	Patient-derived olfactory mucosa cells but not lung or skin fibroblasts mediate axonal regeneration of retinal ganglion neurons. Neuroscience Letters, 2012, 509, 27-32.	1.0	20
39	Long-term persistence of defective HSV-1 vectors in the rat brain is demonstrated by reactivation of vector gene expression. Gene Therapy, 1996, 3, 615-23.	2.3	20
40	Yeast pyruvate carboxylase: Gene isolation. Biochemical and Biophysical Research Communications, 1987, 145, 390-396.	1.0	19
41	Defining Responsiveness of Avian Cochlear Neurons to Brain-Derived Neurotrophic Factor and Nerve Growth Factor by HSV-1-Mediated Gene Transfer. Journal of Neurochemistry, 2002, 70, 2336-2346.	2.1	19
42	Expression of plasminogen activator inhibitor-1 by olfactory ensheathing glia promotes axonal regeneration. Glia, 2011, 59, 1458-1471.	2.5	19
43	Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1. Current Gene Therapy, 2014, 13, 478-491.	0.9	17
44	HSV-1 as a Model for Emerging Gene Delivery Vehicles. ISRN Virology, 2013, 2013, 1-12.	0.5	17
45	Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons. Toxins, 2019, 11, 123.	1.5	15
46	Generation of Highâ€Titer Defective HSVâ€1 Vectors. Current Protocols in Neuroscience, 2013, 62, Unit 4.13.	2.6	13
47	Chronic inhibition of glycogen synthase kinase-3 protects against rotenone-induced cell death in human neuron-like cells by increasing BDNF secretion. Neuroscience Letters, 2012, 531, 182-187.	1.0	12
48	Use of Defective Herpes-Derived Plasmid Vectors. , 1997, 62, 223-232.		11
49	A Neuroregenerative Human Ensheathing Glia Cell Line with Conditional Rapid Growth. Cell Transplantation, 2011, 20, 153-166.	1.2	11
50	Generation of High-Titer Defective HSV-1 Vectors. , 2001, Chapter 4, Unit 4.13.		10
51	Transgenic Mouse Models with Tau Pathology to Test Therapeutic Agents for Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2002, 2, 51-58.	1.1	10
52	A culture model for neurite regeneration of human spinal cord neurons. Journal of Neuroscience Methods, 2011, 201, 346-354.	1.3	9
53	OP18/stathmin binds near the C-terminus of tubulin and facilitates GTP binding. FEBS Journal, 1999, 262, 557-562.	0.2	8
54	Integrating Retroviral Cassette Extends Gene Delivery of HSV-1 Expression Vectors to Dividing Cells. BioTechniques, 2001, 31, 394-405.	0.8	8

#	Article	IF	Citations
55	Gene transfer into Purkinje cells using herpesviral amplicon vectors in cerebellar cultures. Neurochemistry International, 2007, 50, 181-188.	1.9	8
56	Patientâ€derived olfactory mucosa for study of the nonâ€neuronal contribution to amyotrophic lateral sclerosis pathology. Journal of Cellular and Molecular Medicine, 2015, 19, 1284-1295.	1.6	7
57	Expression of the immediate early IE180 protein under the control of the hTERT and CEA tumor-specific promoters in recombinant pseudorabies viruses: Effects of IE180 protein on promoter activity and apoptosis induction. Virology, 2016, 488, 9-19.	1.1	7
58	Vasopressin Decreases Total Free Fatty Acids but Enhances Release of Radioactivity from Isolated Hepatocytes Labelled with [³H]Arachidonic Acid. Hormone and Metabolic Research, 1987, 19, 15-20.	0.7	6
59	Linckosides enhance proliferation and induce morphological changes in human olfactory ensheathing cells. Molecular and Cellular Neurosciences, 2016, 75, 1-13.	1.0	6
60	HSV-1 vector mediated transfer of BDNF into cerebellar granule cells. NeuroReport, 1996, 7, 3105.	0.6	5
61	Differential effects on the survival of neuronal and non-neuronal cells after infection by herpes simplex virus type 1 mutants. Journal of NeuroVirology, 1999, 5, 280-288.	1.0	5
62	Altered Secretome and ROS Production in Olfactory Mucosa Stem Cells Derived from Friedreichâ€™s Ataxia Patients. International Journal of Molecular Sciences, 2020, 21, 6662.	1.8	5
63	Overview of Gene Delivery into Cells Using HSV â€1â€Based Vectors. Current Protocols in Neuroscience, 1999, 6, Unit 4.12.	2.6	4
64	Efficient Transfer of HSV-1 Amplicon Vectors Into Embryonic Stem Cells and Their Derivatives. , 2006, 329, 265-272.		4
65	Gene Therapy Approaches to Ataxias. Current Gene Therapy, 2009, 9, 1-8.	0.9	4
66	Construction and properties of a recombinant pseudorabies virus with tetracycline-regulated control of immediate-early gene expression. Journal of Virological Methods, 2011, 171, 253-259.	1.0	4
67	Synergistic effects of deleting multiple nonessential elements in nonreplicative HSV-1 BAC genomic vectors play a critical role in their viability. Gene Therapy, 2017, 24, 433-440.	2.3	4
68	Engineering nanostructured cell micropatterns on Ti6Al4V by selective ion-beam inhibition of pitting. Corrosion Science, 2020, 167, 108528.	3.0	4
69	Neuronal Models for Studying Tau Pathology. International Journal of Alzheimer's Disease, 2010, 2010, 1-11.	1.1	3
70	A haploid HSVâ€1 genome platform for vector development: testing of the tetracyclineâ€responsive switch shows interference by infected cell protein 0. Journal of Gene Medicine, 2016, 18, 302-311.	1.4	3
71	HSV infection of polarized epithelial cells on filter supports: implications for transport assays and protein localization. European Journal of Cell Biology, 1997, 72, 278-81.	1.6	3
72	Sustained FXN expression in dorsal root ganglia from a nonreplicative genomic HSVâ€1 vector. Journal of Gene Medicine, 2017, 19, 376-386.	1.4	2

#	Article	IF	Citations
73	Phosphorylation, Microtubule Binding and Aggregation of Tau Protein in Alzheimer's Disease. , 0, , 601-607.		0
74	1070. Infectious Delivery and Prolonged Expression of a 135 kb Human Friedreichâ€™s Ataxia Genomic DNA Locus in Human and Mouse Neuronal Cells. Molecular Therapy, 2006, 13, S410-S411.	3.7	0
75	412. A Novel Friedreich's Ataxia Model and In Vivo Gene Rescue Using HSV-1 Amplicon Vectors in Transgenic Mice. Molecular Therapy, 2006, 13, S158.	3.7	0
76	Generation of a lentiviral vector system to efficiently express bioactive recombinant human prolactin hormones. Molecular and Cellular Endocrinology, 2020, 499, 110605.	1.6	0